Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Goldstein

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Topics in Medicinal Chemistry|September 24, 2005
Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for developmentDavid M Goldstein, Tobias Gabriel
Nature Reviews. Drug Discovery|April 12, 2008
High-throughput kinase profiling as a platform for drug discoveryDavid M Goldstein, Nathanael S Gray, Patrick P Zarrinkar
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 3, 2010
Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitorsAndrew J Olaharski, Hans Bitter, Nina Gonzaludo, et al.
Journal of Medicinal Chemistry|November 16, 2012
Rational design of highly selective spleen tyrosine kinase inhibitorsMatthew C Lucas, David M Goldstein, Johannes C Hermann, et al.
Immunohorizons|July 30, 2021
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease ModelsYan Xing, Katherine A Chu, Jyoti Wadhwa, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffoldYan Lou, Zachary K Sweeney, Andreas Kuglstatter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 6, 2021
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated DiseaseClaire L Langrish, J Michael Bradshaw, Michelle R Francesco, et al.
Molecular Cancer Therapeutics|October 6, 2017
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug ClearanceEleni Venetsanakos, Ken A Brameld, Vernon T Phan, et al.
Journal of Medicinal Chemistry|July 1, 2017
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid TumorsKen A Brameld, Timothy D Owens, Erik Verner, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2008
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivityRonald J Hill, Karim Dabbagh, Deborah Phippard, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Topics in Medicinal Chemistry|September 24, 2005
Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for developmentDavid M Goldstein, Tobias Gabriel
Nature Reviews. Drug Discovery|April 12, 2008
High-throughput kinase profiling as a platform for drug discoveryDavid M Goldstein, Nathanael S Gray, Patrick P Zarrinkar
Toxicological Sciences : an Official Journal of the Society of Toxicology|September 3, 2010
Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitorsAndrew J Olaharski, Hans Bitter, Nina Gonzaludo, et al.
Journal of Medicinal Chemistry|November 16, 2012
Rational design of highly selective spleen tyrosine kinase inhibitorsMatthew C Lucas, David M Goldstein, Johannes C Hermann, et al.
Immunohorizons|July 30, 2021
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease ModelsYan Xing, Katherine A Chu, Jyoti Wadhwa, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2014
Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffoldYan Lou, Zachary K Sweeney, Andreas Kuglstatter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 6, 2021
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated DiseaseClaire L Langrish, J Michael Bradshaw, Michelle R Francesco, et al.
Molecular Cancer Therapeutics|October 6, 2017
The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug ClearanceEleni Venetsanakos, Ken A Brameld, Vernon T Phan, et al.
Journal of Medicinal Chemistry|July 1, 2017
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid TumorsKen A Brameld, Timothy D Owens, Erik Verner, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2008
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivityRonald J Hill, Karim Dabbagh, Deborah Phippard, et al.
Pageof 3